Skip to main content
Premium Trial:

Request an Annual Quote

Adnavance Raises $3.7M in Series B Financing

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Adnavance Technologies said today it has taken in CDN$3.7 million (US$3.7 million) in a Series B financing.
 
The funding round was headed by Working Opportunity Fund, which is managed by GrowthWorks Capital, JovInvestment Management, and Business Development Bank of Canada.
 
Adnavance, which has its headquarters in Vancouver, British Columbia, and a lab in Saskatoon, Saskatchewan, plans to use the funds to continue to develop and expand its metalized-DNA technology, which the company said “may eliminate the need for target amplification for a large number of molecular diagnostic tests.”
 
Adnavance also said it has named former Nanogen and Xenomics CEO Randy White to be CEO of the company.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.